close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Femasys Inc.

< Previous 1 2 3 Next >
Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Pricing of $8.0 Million Underwritten Public Offering
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Second Quarter Financial Results for 2025
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Israeli Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Partnership with HRC Fertility, Esteemed Conglomerate Provider of Fertility Services in Western U.S., to Offer FemaSeed
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
From Femasys Inc.
Via GlobeNewswire
Tickers FEMY
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today